Responder analysis was conducted to evaluate the percentage of patients achieving complete symptom resolution across 13 ...

Q1 2025 Management View CEO Brian Lian highlighted the company's progress in advancing its VK2735 obesity program, with Phase ...

"On behalf of Renibus and the clinical study team ... enrollment and administration of RBT-1 in its PROTECT Phase 3 pivotal trial and announced completion of enrollment in April 2025.

A grassroots organization that formed with the goal of recalibrating cancer care around patient needs issued guidance ...

BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that it will present additional results from the Phase 3 PANOVA-3 ... or completed clinical trials exploring the ...

Dr. DeWeese has no relationship with Candel, other than serving as the national principal investigator for Candel’s phase 3 clinical trial of CAN-2409 in patients with intermediate-to-high risk ...

Novocure (NVCR) announced that it will present additional results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields therapy for ...

representing a significant clinical advantage. The efficacy appears higher than previously reported in the US Phase 3 trial 3,4 and adds to a growing body of evidence. Recent real-world data was ...

VivaVision Biotech reveals promising phase 2 trial results for VVN461, a new treatment for Non-Infectious Anterior Uveitis, ...

In a phase 3, double-blind trial, we randomly assigned patients ... trial and their family members and caregivers, as well as the clinical research teams and support staff at the trial sites ...